AI Article Synopsis
Article Abstract
Background/aims: Hepatocellular carcinoma is a major cause of mortality and morbidity in both cirrhotic and non-cirrhotic patients, and most patients are suitable for locoregional and/or systemic therapy at the time of diagnosis. In this study, we aimed to determine the efficacy and safety of transarterial radioembolization in elderly patients.
Materials And Methods: Patients diagnosed with hepatocellular carcinoma between 2013 and 2022 were screened retrospectively. The patients were divided into 2 groups: the elderly (age >70 years) and the young (age <70 years). Transarterial radioembolization response was evaluated according to the Response Evaluation Criteria in Solid Tumors.
Results: Ninety patients were included in the young group, and 56 patients were in the elderly group. It was observed that male dominance was less in the elderly group (P > .05). Hepatitis B was the most common cause in both groups. There were no significant differences between groups with regard to morphological features of tumors [tumor focality (single; 62.2% and 60.7%, respectively) and maximal tumor diameter (6.9 and 6.55 cm, respectively)], transarterial radioembolization responses (51.1% and 39.3%, respectively), survival (9 and 8.5 months), and both early and late side effects (P > .05). Age was not found to be an effective factor in transarterial radioembolization response (P > .05).
Conclusion: No differences in the safety and efficacy of transarterial radioembolization were observed between the groups. In addition, it was observed that age was not a predictive factor for adverse events. In elderly patients in the frail group, it should be considered that age alone should not be seen as a limitation in the transarterial radioembolization decision.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11059000 | PMC |
| http://dx.doi.org/10.5152/tjg.2024.23155 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transarterial Radioembolization with Yttrium-90 Resin Microspheres for Huge Focal Nodular Hyperplasia.
Cardiovasc Intervent Radiol
December 2024
Ytrrium-90 Precision Interventional Radiotherapy Center of Liver Cancer, SchoolofClinicalMedicine, Beijing Tsinghua Changgung Hospital, TsinghuaUniversity, Beijing, China.
Radioembolization for Hepatocellular Carcinoma: a Comparison on Dual-phase Cone-beam CT, Contrast-enhanced CT (CECT) and Tc-macroaggregated albumin-SPECT/CT in predicting final distribution volumes and dosimetry of the post-embolization Y PET/CT.
Radiol Med
December 2024
Department of Radiology, IRCCS Ospedale San Raffaele, Milan, Italy.
Purpose: Personalized treatment schemes are being systematically applied to ensure best treatment outcome in oncologic patients. This is true also for personalized dosimetry in transarterial radioembolization (TARE) in hepatocellular carcinoma (HCC) patients. Precise and detailed volumetric and functional data derived from radiological and nuclear imaging methods are essential for personalized dosimetry.
View Article and Find Full Text PDFTc/Y radiolabeled biodegradable gel microspheres for lung shutting fraction assessment and radioembolization in hepatocellular carcinoma theranostics.
Mater Today Bio
December 2024
State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, Soochow University, Suzhou, 215123, China.
Transarterial radioembolization (TARE) is a well-established clinical therapy for the treatment of patients with intermediate to advanced hepatocellular carcinoma (HCC) or those who are ineligible for radical treatment. However, commercialized radioactive microspheres still have some issues, such as high density, complicated preparation, non-biodegradability. Furthermore, the use of different radioactive microspheres during TARE and lung shunt fraction assessment has led to inconsistencies in biodistribution in certain cases.
View Article and Find Full Text PDFSelective internal radiation therapy across Barcelona Clinic Liver Cancer (BCLC) stages of hepatocellular carcinoma: literature review.
Hepatobiliary Surg Nutr
December 2024
Department of Hepatology, Assistance Publique-Hôpitaux de Paris, Henri Mondor-Albert Chenevier University Hospital, Créteil, France.
Background And Objective: Selective internal radiation therapy (SIRT) represents an endovascular treatment option for patients with hepatocellular carcinoma (HCC). Its use is widely recognized in the intermediate and advanced HCC, but it has become more prevalent in recent years in different Barcelona Clinic Liver Cancer (BCLC) stages. The aim of this review is to summarize the role of SIRT and its clinical implications through different stages of HCC.
View Article and Find Full Text PDFPredicting treatment responses using magnetic resonance imaging-based radiomics in hepatocellular carcinoma patients undergoing transarterial radioembolization.
Rev Assoc Med Bras (1992)
December 2024
Çukurova University, Balcali Hospital, Medical School, Department of Radiology - Adana, Turkey.
Objective: This study evaluates the efficacy of magnetic resonance imaging-based radiomics in predicting treatment responses in hepatocellular carcinoma patients undergoing transarterial radioembolization.
Methods: Pre-treatment magnetic resonance imaging scans from 65 hepatocellular carcinoma patients were analyzed. Radiomic features were extracted from axial T1-weighted and T2-weighted sequences using a standardized workflow involving image preprocessing, segmentation, and feature extraction.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!